146 related articles for article (PubMed ID: 28968716)
1. Dependent generalized Dirichlet process priors for the analysis of acute lymphoblastic leukemia.
Barcella W; De Iorio M; Favaro S; Rosner GL
Biostatistics; 2018 Jul; 19(3):342-358. PubMed ID: 28968716
[TBL] [Abstract][Full Text] [Related]
2. Monitoring asparaginase activity in middle-income countries.
Cecconello DK; Werlang ICR; Alegretti AP; Hahn MC; de Magalhães MR; Battistel AP; Zenatti PP; Yunes JA; Cabreira-Cagliari C; Rechenmacher C; Goldani MZ; Daudt LE; Michalowski MB
Lancet Oncol; 2018 Sep; 19(9):1149-1150. PubMed ID: 30078698
[No Abstract] [Full Text] [Related]
3. Pharmacology of PEG-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Pinheiro JP; Lanvers C; Würthwein G; Boos J
Blood; 2002 Sep; 100(5):1923-4; author reply 1924-5. PubMed ID: 12211194
[No Abstract] [Full Text] [Related]
4. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
[TBL] [Abstract][Full Text] [Related]
5. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
[TBL] [Abstract][Full Text] [Related]
6. Platelet aggregation is stimulated by L-asparginase in children with acute lymphoblastic leukemia and normal individuals.
Jaime-Perez JC; Gomez-Almaguer D
Haematologica; 2002 Aug; 87(8):891-2. PubMed ID: 12161371
[No Abstract] [Full Text] [Related]
7. Asparaginase in acute lymphoblastic leukemia.
Kawedia JD; Rytting ME
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S14-7. PubMed ID: 25486949
[TBL] [Abstract][Full Text] [Related]
8. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.
Sassen SD; Mathôt RA; Pieters R; Kloos RQ; de Haas V; Kaspers GJ; van den Bos C; Tissing WJ; Te Loo M; Bierings MB; Kollen WJ; Zwaan CM; van der Sluis IM
Haematologica; 2017 Mar; 102(3):552-561. PubMed ID: 28250007
[TBL] [Abstract][Full Text] [Related]
10. Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase.
Hlozkova K; Pecinova A; Alquezar-Artieda N; Pajuelo-Reguera D; Simcikova M; Hovorkova L; Rejlova K; Zaliova M; Mracek T; Kolenova A; Stary J; Trka J; Starkova J
BMC Cancer; 2020 Jun; 20(1):526. PubMed ID: 32503472
[TBL] [Abstract][Full Text] [Related]
11. Thyroid function is not affected by second exposure to erwinia asparaginase for childhood acute lymphoblastic leukemia.
Bossi G; Larizza D; Conter V
Haematologica; 1997; 82(4):507-8. PubMed ID: 9299875
[No Abstract] [Full Text] [Related]
12. Erroneous exchange of asparaginase forms in the treatment of acute lymphoblastic leukemia.
Cheung KC; van den Bemt PM; Torringa ML; Tamminga RY; Pieters R; de Smet PA
J Pediatr Hematol Oncol; 2011 Apr; 33(3):e109-13. PubMed ID: 21368672
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.
Narta UK; Kanwar SS; Azmi W
Crit Rev Oncol Hematol; 2007 Mar; 61(3):208-21. PubMed ID: 17011787
[TBL] [Abstract][Full Text] [Related]
14. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
Rizzari C; Valsecchi MG; Aricò M; Conter V; Testi A; Barisone E; Casale F; Lo Nigro L; Rondelli R; Basso G; Santoro N; Masera G;
J Clin Oncol; 2001 Mar; 19(5):1297-303. PubMed ID: 11230471
[TBL] [Abstract][Full Text] [Related]
15. [Effect of E coli or Erwinia asparaginase and corticotherapy on fibrinogen concentration in induction of acute lymphoblastic leukemia in children].
Astruc D; Nowak V; Grunebaum L; Wiesel ML; Cazenave JP; Babin-Boilletot A; Lutz P
Arch Pediatr; 1994 Jun; 1(6):617-8. PubMed ID: 7994359
[No Abstract] [Full Text] [Related]
16. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Ebeid EN; Kamel MM; Ali BA
J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
[TBL] [Abstract][Full Text] [Related]
17. How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review.
Brigitha LJ; Pieters R; van der Sluis IM
Eur J Cancer; 2021 Nov; 157():238-249. PubMed ID: 34536947
[TBL] [Abstract][Full Text] [Related]
18. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
19. Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase.
Panetta JC; Liu Y; Swanson HD; Karol SE; Pui CH; Inaba H; Jeha S; Relling MV
Pediatr Blood Cancer; 2020 Jul; 67(7):e28244. PubMed ID: 32323890
[TBL] [Abstract][Full Text] [Related]
20. Dynamic changes in specific anti-L-asparaginase antibodies generation during acute lymphoblastic leukemia treatment.
Walenciak J; Wyka K; Janczar S; Młynarski W; Zalewska-Szewczyk B
Pharmacol Rep; 2019 Apr; 71(2):311-318. PubMed ID: 30826572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]